Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2008-06-18
2010-10-19
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S141100, C424S155100
Reexamination Certificate
active
07815906
ABSTRACT:
Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist.
REFERENCES:
patent: 5416192 (1995-05-01), Shoyab et al.
patent: 5709858 (1998-01-01), Godowski et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 6511986 (2003-01-01), Zhang et al.
patent: 6558668 (2003-05-01), Liau
patent: 6570002 (2003-05-01), Hardwick et al.
patent: 6586395 (2003-07-01), Kiefer et al.
patent: 6670183 (2003-12-01), Serrero
patent: 6720159 (2004-04-01), Serrero
patent: 6824775 (2004-11-01), Serrero
patent: 6881548 (2005-04-01), Serrero
patent: 7091047 (2006-08-01), Serrero
patent: 7368428 (2008-05-01), Serrero
patent: 7411045 (2008-08-01), Serrero et al.
patent: 2002/0094966 (2002-07-01), Serrero
patent: 2003/0092661 (2003-05-01), Serrero
patent: 2003/0215445 (2003-11-01), Serrero
patent: 2004/0131618 (2004-07-01), Serrero
patent: 2005/0106150 (2005-05-01), Serrero
patent: 2005/0175616 (2005-08-01), Kiener et al.
patent: 2007/0015225 (2007-01-01), Serrero
patent: 2007/0065887 (2007-03-01), Kinch et al.
patent: 2008/0114070 (2008-05-01), Serrero
patent: 2008/0145369 (2008-06-01), Serrero
patent: 2008/0311120 (2008-12-01), Serrero et al.
patent: 2009/0010931 (2009-01-01), Serrero
patent: 2009/0203047 (2009-08-01), Serrero
patent: WO-9115510 (1991-10-01), None
patent: WO-93/15195 (1993-08-01), None
patent: WO-98/52607 (1998-03-01), None
patent: WO-02/31198 (2002-04-01), None
patent: WO-02102229 (2002-12-01), None
patent: WO-02102306 (2002-12-01), None
patent: WO-2004039244 (2004-05-01), None
patent: WO-2004045544 (2004-06-01), None
patent: WO-2004060280 (2004-07-01), None
patent: WO-2004078782 (2004-09-01), None
patent: WO-2005/000207 (2005-01-01), None
patent: WO-2005000240 (2005-01-01), None
patent: WO-2005011590 (2005-02-01), None
patent: WO-2006044566 (2006-04-01), None
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Boon (Adv Can Res, 1992, 58:177-210).
Weiner L.M., Seminars Oncology, vol. 26, No. 4, Suppl 12, pp. 41-50, 1999.
J. Barnwell, et al., “A Human 88-kD Membrane Glycoprotein (CD36) Functions in Vitro as a Receptor for a Cytoadherence Ligand on Plasmodium falciparum-infected Erythrocytes,” J. Clin. Invest., Sep. 1989, vol. 84, pp. 765-772.
A. Bateman et al., “Granulins, a Novel Class of Peptide from Leukocytes,” Biochemical and Biophysical Research Communications, vol. 173, No. 3, 1990, pp. 1161-1168.
V. Bhandari et al., “Isolation and sequence fo the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains,” Proc. Natl. Acad. Sci. USA, vol. 89, Mar. 1992, pp. 1717-1719.
R. Daniel, et al., “Cellular localization of Gene Expression for Progranulin,” Journal of Histochemistry and Cytochemistry, Jul. 2000, vol. 48, No. 7, pp. 999-1009.
Hoque, et al., “The growth factor granulin interacts with cyclin T1 and modulates P-TEfb-dependent transcription,” Mol Cell Biol., Mar. 2003, vol. 23, No. 5, pp. 1688-1702.
MB Jones et al., “The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer,” Clin Cancer Res., Jan. 2003, vol. 9, No. 1, pp. 44-51.
WE Kim et al., “PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells,” Clin Cancer Res. Jul. 15, 2006, vol. 12, pp. 4192-4199.
C. Landry, et al., Expression of Oligodendrocytic mRNAs in Glial Tumors: Changes Associated with Tumor Grade and Extent of Neoplastic Infiltration1, Cancer Research, Sep. 15, 1997, vol. 57, pp. 4098-4104.
L. M. Liau, et al., “Identification of a Human Glioma-associated Growth Factor Gene,granulin,Using Differential Immuno-absorption1,” Cancer Research, Mar. 1, 2000, vol. 60, pp. 1353-1360.
R. Lu et al., “Stimulation of PC cell-derived growth factor (epithelin/granulin precursor) expression by estradiol in human breast cancer cells,” Biochem Biophys Res Commun., Mar. 5, 1999, vol. 256, No. 1, pp. 204-207.
R. Lu et al., “Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells,” J Cell Physiol., Jun. 1999, vol. 179, No. 3, pp. 297-304.
G. Monami et al., “Proepithelin Regulates Prostate Cancer Cell Biology by Promoting Cell Growth, Migration, and Anchorage-Independent Growth”, Am J. Pathol., Mar. 2009, vol. 174, No. 3, pp. 1037-1047.
CX. Pan et al., “PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma,” Clin Cancer Res., Feb. 15, 2004, vol. 10, No. 4, pp. 1333-1337.
G. Plowman et al., “The Epithelin Precursor Encodes Two Proteins with Opposing Activities on Epithelial Cell Growth,” The Journal of Biological Chemistry, vol. 267, No. 18, 1992, pp. 13073-13078.
G. Serrero et al., “An In Vitro Model to Study Adipose Differentiation in Serum-Free Medium,” Analytical Biochemistry, vol. 120, 1982, pp. 351-359.
G. Serrero, “Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis,” Biochem Biophys Res Commun., Aug. 29, 2003, vol. 3, pp. 409-413.
G. Serrero, “Endocrine and autocrine control of growth and differentiation of teratoma-derived cell lines,” Prog. Clin. Bio. Res., 1986, vol. 226, pp. 191-204.
G. Serrero, et al., IHC Study of a novel molecular marker of infiltrating ductal carcinoma, The third Era of Hope meeting for the Department of Defense (DOD) Breast Cancer Research Program (BCRP) held Sep. 25-28, 2002.
W. Tangkeangsirisin et al., “PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells,” Carcinogenesis, Sep. 25, 2004, vol. 9, pp. 1587-1592.
W. Tangkeangsirisin et al., “PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cell,” Cancer Res. Mar. 1, 2004, vol. 64, No. 5, pp. 1737-1743.
H.E. Turner et al., “Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland,” Clinical Endocrinology, (2000), vol. 53, pp. 337-344.
H. Zhang et al., “Inhibition of tumorigenicity of the teratoma PC cell line by transfection with antisense cDNA for PC cell-derived growth factor (PCDGF, epithelin/granulin precursor),” Proc Natl Acad Sci USA Nov. 24, 1998, vol. 95, No. 24, pp. 14202-14207.
W. Wang et al., “PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma,” Clin Cancer Res. Jan. 1, 2006, vol. 12, No. 1, pp. 49-56.
W. Wang et al., “PC-Cell Derived Growth Factor (PCDG, progranulin) Expression and Action in Human Multiple Myelomas,” Proceedings of American Association for Cancer Research, Mar. 2001, vol. 42, p. 835.
W. Wang et al., “PC cell-derived growth factor (granulin precursor) expression and action in human multiple myeloma,” Clin Cancer Res., Jun. 2003, vol. 9, No. 6, pp. 2221-2228.
X. Xia et al., “Identification of cell surface binding sites for PC cell-derived growth factor, PCDGF, (epithelin/granulin precursor) on epithelial cells and fibroblasts,” Biochem Biophys Res Commun, Apr. 17, 1998, vol. 245, No. 2, pp. 539-543.
T. Zanocco-Marani, et al., “Biological Activities and Signaling Pathways of the Granulin/Epithelin Precursor,” Cancer Research, Oct. 15, 1999, vol. 59, No. 20, pp. 5331-5340.
J. Zhou et al., “Purification of an Autocrine Growth Factor Homologous with Mouse Epithelin Precursor from
A & G Pharmaceutical, Inc.
Goddard Laura B
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Compositions and methods for restoring sensitivity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for restoring sensitivity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for restoring sensitivity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176239